Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone857-246-8998
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.10 million
Profitability
Miscellaneous
Employees107
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) released its earnings results on Monday, March, 18th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. The biotechnology company had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.92 million. Pieris Pharmaceuticals had a negative return on equity of 54.54% and a negative net margin of 91.93%. View Pieris Pharmaceuticals' Earnings History.
When is Pieris Pharmaceuticals' next earnings date?
What price target have analysts set for PIRS?
2 analysts have issued 1 year target prices for Pieris Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 73.0% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.
What is the consensus analysts' recommendation for Pieris Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.
What are Wall Street analysts saying about Pieris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. " (4/19/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $5 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Pieris Pharmaceuticals, Inc." (3/19/2019)
Has Pieris Pharmaceuticals been receiving favorable news coverage?
News coverage about PIRS stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), US Stem Cell (USRM), Protalex (PRTX) and ALGAE TEC LTD/S (ALGXY).
What other stocks do shareholders of Pieris Pharmaceuticals own?
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
- Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
- Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
- Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
- Maria Kelman, Director of Investor Relations
Who are Pieris Pharmaceuticals' major shareholders?
Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include P.A.W. Capital Corp (0.51%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Which major investors are selling Pieris Pharmaceuticals stock?
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $2.89.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $142.05 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.
What is Pieris Pharmaceuticals' official website?
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
